AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient’s tumor. Our tests improve the classification of cancer, both primary and metastatic, and support physicians by providing more specific prognosis and individual risk assessments for their patients.

AviaraDx offers diagnostic tests to qualified physicians or laboratories through its certified CLIA laboratory service operations. The company's first four diagnostic test offerings, based on its proprietary technologies used in molecular classification of cancers, are:

• Aviara CancerTYPE ID®- for improved cancer classification, especially in patients diagnosed with metastatic cancer where the origin is uncertain or unknown.
• Aviara H/I^SM for assessment of endocrine resistance and risk of recurrence in certain breast cancers.
• Aviara MGI^SM for objective measurement of tumor grade and prediction of chemosensitivity in ER+ breast tumors
• Aviara Breast Cancer Index^SM - By combining the results of the Aviara H/I and MGI tests, a combined risk analysis can be calculated for better stratification of ER-positive, node-negative breast cancer patients. The Aviara Breast Cancer Index provides a more complete picture of both recurrence risk and therapeutic options for each individual patient.

All tests are real time, RT-PCR based, assays that are compatible with readily available, formalin-fixed, paraffin embedded (FFPE) needle core biopsies, excisional biopsies and/or surgical samples.